Biotech Startups

Arboretum is a venture capital firm focused on investing in early-stage healthcare entrepreneurs and portfolio companies. The firm leverages an active network of advisors with deep expertise in medical devices, diagnostics, health policy, and clinical innovation.

1 investor

Azurity Pharmaceuticals develops and commercializes innovative medicines across 10 therapeutic areas for overlooked patient populations, serving over 50 countries with a portfolio of more than 50 medicines across various dosage forms. The company uses data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.

1 investor

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development. It focuses on drug development, partnerships, and licensing deals within the biopharma sector.

1 investor

ARC Medical develops liquid medical devices, including its JOCOAT and IPCOAT products, that create a temporary physical barrier during arthroscopy, laparoscopy, or open surgery to prevent or reduce surgical adhesions. The products are aimed at improving patient recovery and are intended for surgeons and healthcare providers performing surgical procedures.

1 investor

Arcadia Biosciences develops specialty wheat ingredients with enhanced nutritional profiles — such as higher fiber, improved protein, reduced gluten, and longer shelf life — working with food manufacturers and processors to reformulate wheat-based products. The company also markets Zola coconut water, a consumer beverage brand.

1 investor

BioSTL is a St. Louis-based coalition, active since 2001, that works to grow the region's bioscience innovation sector and translate it into local economic development. It supports bioscience research, companies, and opportunity in the St. Louis area.

1 investor

Archean develops in vitro platforms using human neurons for continuous drug testing, aiming to improve translatability in neurological drug research. It offers closed-loop testing across drug candidates for the treatment of neurological conditions.

1 investor

Arctech is a contract research organisation (CRO) and co-development partner that helps organisations develop, test, and commercialise pest, vector, and disease detection and control technologies. It combines expertise in entomology, chemistry, public health, regulatory science, AI, and odour sensing to support product development across household pests, animal and human health, and agriculture.

1 investor

Arcturis provides research-ready, regulatory-grade real-world health data and analytics for clinical research and drug development, leveraging a UK-based network of enriched electronic health records and multi-modal patient data. The company generates real-world evidence insights to support clinical trials, external control arms, and health technology assessments.

1 investor

Arcturus develops messenger RNA therapeutics and vaccines targeting rare genetic diseases and infectious pathogens, including a self-amplifying mRNA COVID-19 vaccine approved in Japan and Europe, along with clinical-stage candidates for cystic fibrosis and ornithine transcarbamylase deficiency.

1 investor

Ardan Pharma is a biotech company developing small-molecule modulators of the TMEM176A/B cation channel as a targeted cancer immunotherapy for oncology indications with unmet medical needs. Incorporated in Delaware with operations in Uruguay and Argentina, it is advancing drug candidates from pre-IND toward clinical stage.

1 investor

Ardigen is an AI-driven Contract Research Organization providing bioinformatics and machine learning solutions to accelerate drug discovery for biotech and pharmaceutical companies. The company leverages artificial intelligence, computational biology, and software engineering to help clients identify drug candidates and increase the probability of clinical success.

1 investor

B-FLEXION is an investment group with a heritage in biopharmaceuticals spanning three generations, operating asset managers across multiple investment areas and holding stakes in transformative operating businesses.

1 investor

Argenta Global is a contract research and manufacturing organization (CRO/CDMO) specializing in animal health, providing comprehensive support across the product development lifecycle from molecule to market for companion and farm animal treatments.

1 investor

Argobio is an operational venture builder in biotechnology sponsored by five strategic investors including venture capital and pharmaceutical partners. The company supports biotech innovation through partnerships with leading healthcare and research organizations.

1 investor

Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.

1 investor

Argonaut Manufacturing Services provides contract manufacturing for life sciences and healthcare products, serving partners across the health and biotech industries with expertise in cGMP manufacturing, regulatory affairs, and operational scaling.

1 investor

ArgusEye develops LSPR-based biosensor systems for real-time monitoring and analytics of bioprocesses in biopharmaceutical development and manufacturing. Its patented Auga platform combines sensor hardware, sensor chips, and software to track critical quality attributes and process parameters, including in-line detection of antibody aggregates and fragments during purification.

1 investor

Aridhia develops the Digital Research Environment (DRE), a trusted research platform for biomedical and health informatics that enables researchers across multiple countries to collaborate on health research and data-intensive health delivery programs. The platform addresses regulatory compliance, data management, and collaboration challenges in scaling health research initiatives.

1 investor

Medical device company for neurosurgical treatment of intracranial hypertension. Acquired in 2019.

1 investor

ArmaBio develops a reprogrammable bioelectronic biosensing platform that detects biomarkers from small samples of blood, saliva, urine, or plasma with lab-grade accuracy in minutes. It provides this sensing layer as infrastructure for point-of-care, home, remote monitoring, pharma, and consumer health diagnostics companies.

1 investor

ArmaGen develops blood-brain-barrier-crossing protein therapies for lysosomal storage disorders; acquired by JCR Pharmaceuticals in 2020.

1 investor

ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.

1 investor

ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]

1 investor